Veeva Systems (VEEV) Q3 2025 earnings summary

Executive summary

• Q3 FY2025 revenue reached $699 million, up 13% year-over-year, exceeding guidance, with non-GAAP operating income of $304 million and a record 43.5% margin, driven by strong execution and innovation across R&D and Commercial segments.

• Subscription services accounted for 83% of total revenues, growing 17% year-over-year, while professional services revenue declined slightly.

• Net income for the quarter rose 37% year-over-year to $186 million, with diluted EPS of $1.13.

• Strategic partnerships expanded, including top 20 biopharma commitments and Walgreens, and new AI-driven solutions were launched.

• Liquidity remained strong with over $5.0 billion in cash, cash equivalents, and short-term investments at quarter-end.

Financial highlights

• Total revenue grew 13% year-over-year to $699 million; subscription revenue rose 17% to $581 million, while professional services revenue declined 3% to $118 million.

• Non-GAAP operating income was $304 million, with a record 43.5% operating margin; GAAP operating income was $181 million, up 41% year-over-year.

• Non-GAAP total gross margin for Q3'25 was 77.3%, with subscription gross margin at 86.2% and services gross margin at 33.5%.

• Cash flow from operations for the nine months was $1.02 billion, and cash, cash equivalents, and short-term investments exceeded $5.0 billion.

• Deferred revenue stood at $739.7 million as of October 31, 2024.

Outlook and guidance

• FY2025 revenue guidance raised to $2.722–$2.725 billion, with non-GAAP operating income expected at ~$1.12 billion and non-GAAP EPS at ~$6.44.

• Q4 FY2025 revenue expected between $696–$699 million, with non-GAAP operating income of ~$275 million and EPS of ~$1.57.

• FY2025 non-GAAP operating margin projected at 41%; Q4 non-GAAP operating margin expected at 39%.

• Management expects R&D Solutions to continue increasing as a percentage of total revenues.

• No formal FY2026 guidance provided; will be given after Q4 results.